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Abstract
Background: Adult Langerhans cell histiocytosis (LCH) is an orphan disease. Chemotherapy is usually reserved to
patients presenting with single system multifocal (SS-m) or multisystem (MS) disease but due to the lack of
randomized studies no standard first line therapy has been defined yet. Pediatric regimens based on the
vinblastine/prednisone backbone are not well tolerated in adults and probably less effective. We previously
demonstrated high efficacy of the dose dense polichemotherapy regimen MACOP-B in 7 adult patients with SS-m
or MS-LCH, in terms of high response rate and durable responses. Here we report an update of these data with the
purpose of evaluating the long term efficacy of MACOP-B in adult LCH.
Methods: Clinical data of all adult LCH patients (n = 17) diagnosed and treated at our Institution during the past
20-year period were retrospectively reviewed.
Results: A total of 11 patients (6 with SS-m and 5 with MS-LCH) were treated with MACOP-B from 1995 to 2014.
The overall response rate was confirmed to be 100 %, with a complete response of 73 % and a partial response
rate of 27 %. Overall progression free survival was 64 %, and disease free survival after achievement of initial CR was
87 %. Overall survival rate was 82 % after 6.7 years of median follow-up.
Conclusions: These data confirm high activity of MACOP-B in adult LCH, indicating that a substantial fraction of
patients achieve long lasting responses and can be cured with this therapeutic approach.
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Background
Langerhans cell histiocytosis (LCH) is a rare, heteroge-
neous and potentially debilitating disease [1]. Highest in-
cidence is observed among children with 2–10 cases per
million, whereas in adults LCH affects only one or two
cases per million and it is thus considered an orphan
disease [1]. Due to its rarity and lack of prospective ran-
domized trials there is no specific therapy for adult LCH
and treatment schedules have been derived so far from
pediatric protocols [2]. Chemotherapy is reserved to pa-
tients with single system multifocal (SS-m) or multisys-
tem (MS) disease [3]. Since more than 25 years, the back
bone of pediatric chemotherapeutic protocols is the
combination of vinblastine and steroids, followed by
therapy consolidation [3]. Given that early response
emerged as an important prognostic predictor, efforts
have been made to intensify the induction therapy by
adding etoposide (in the LCH II trial) [4] or methotrex-
ate (in the LCH III study) [5] to the standard vinblastine
based regimen. These efforts were especially directed to
treatment of patients with involvement of risk organs
(RO). Nevertheless the results of these approaches were
not deemed satisfactory, as no major differences in the
final outcome were observed [4]. On the other hand the
results of the LCH III trial suggested that milder induc-
tion but longer therapy duration could significantly
improve the outcome by reducing recurrences [5]. Al-
though with the 3 LCH trials substantial progresses have
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been made in the treatment of pediatric LCH, this thera-
peutic strategy is unlikely to be successful in adults, as
the only prospective randomized trial evaluating the
efficacy of vinblastine/prednisone regimen in adults
(LCHA1 trial) was prematurely closed for unacceptable
toxicities (vinblastine related neurotoxicity and detrimen-
tal effects of prolonged steroid therapy) [3]. Moreover re-
cent studies seem to indicate that this approach might
have lower efficacy in adults compared to children, sug-
gesting that adult and pediatric LCH could harbor differ-
ent biological characteristics [6, 7]. In conclusion, available
data do not support the use of pediatric regimens in adult
LCH, indicating that the concept of mild induction
followed by maintenance therapy probably cannot be
translated to adults. Alternative approaches tested in adult
LCH include nucleoside analogs such as cytarabine and
cladribine (2-CDA) [6, 8] but no consensus on the best
frontline treatment strategy has been reached yet.
We previously described our experience with the
dose dense short course polichemotherapy regimen
MACOP-B (Methotrexate, Doxorubicin, Cyclophos-
phamide, Vincristine, Bleomycin, Prednisone) in 7
adult patients affected by SS-m or MS LCH [9], dem-
onstrating high activity in terms of overall response
rate (ORR) and long term disease control, despite the
lack of maintenance therapy and an overall treatment
duration of only 3 months.
Here we report the updated long term results of our
experience with the MACOP-B regimen in the treatment
of 11 adult LCH patients.
Patients and methods
Data on 17 consecutive adult patients affected by LCH
diagnosed and treated at our institution between 1995
and 2014 were retrospectively reviewed. For an institu-
tional policy, in the absence of conclusive data and
international guidelines on the best first line therapy,
eligible patients with SS-m or MS-LCH were treated
with the MACOP-B regimen. Eligibility criteria in-
cluded age > 18 years, normal electrocardiography, ad-
equate blood cell counts (white blood cells >3000/μL,
hemoglobin > 10 g/dl, platelets > 100,000/ μL), normal
liver and renal laboratory tests. Laboratory tests were
repeated before the start of each chemotherapy cycle.
All patients had biopsy proven diagnosis of LCH, and
all biopsies were reviewed at our Institution. Staging
procedures and response assessments and criteria were
previously described [9]: briefly, complete response
(CR) was defined as no evidence of active disease with
regression of signs and symptoms at physical examin-
ation and imaging studies. A partial response (PR) was
defined as a reduction of >50 % of all measurable and
active disease. Initial staging included physical examin-
ation, complete endocrinological assessment, total-body
computed tomography (CT) scan, complete skeletal
X-ray, bone marrow biopsy and bone scan. All patients
enrolled after the year 2002 (n = 8) underwent positron
emission tomography (PET) scan. Patients with bone le-
sions were also evaluated with magnetic resonance im-
aging (MRI). Restaging was done after 6 weeks (interim
evaluation) and 4 weeks after the completion of the last
chemotherapy course with total-body CT scan, skeletal X-
ray, MRI and bone scan in case of bone lesions and PET
scan when feasible (8 patients).
Follow-up assessments were performed every 3 months
during the first year and every 6 months starting from
the third to the fifth year and every 12–18 months for
the further follow-up.
MACOP-B regimen was administered weekly in out-
patient basis for 12 weeks as reported previously [9]:
cyclophosphamide 350 mg/m2 and doxorubicin 50 mg/mq
given i.v. on days 1, 15, 29, 43, 57 and 71; methotrexate
400 mg/m2 on days 8, 36 and 64 followed by leucovorin
rescue; vincristine 1.4 mg/m2 on days 8, 22, 36, 50 and 64;
bleomycin 10 mg/m2 on days 22, 50 and 78 and prednisone
40 mg/m2 on days 1–84. The treatment algorithm is
depicted in Fig. 1.
The study was approved by our institutional review
board and by the Ethical Committee (Azienda Ospeda-
liera di Bologna, Policlinico S.Orsola-Malpighi) and reg-
istered in the Italian Registry of Observational Studies.
All participants gave written informed consent in ac-
cordance with the Declaration of Helsinki.
Overall survival (OS) was calculated from the time of
initial diagnosis until last follow-up or death. Progres-
sion free survival (PFS) was calculated from the start of
chemotherapy until disease progression or last follow-
up. Disease free survival (DFS) was calculated from the
achievement of complete response after MACOP-B chemo-
therapy until relapse or last follow-up.
OS, PFS and DFS curves were analyzed with the
Kaplan-Meier method [10].
Results
From 1995 to 2014, 17 adult patients affected by LCH
were treated at our institution. Four patients with
monofocal LCH underwent local treatment strategies
(surgery in 2 patients and radiotherapy in 2 patients).
One patient with pulmonary LCH who relapsed after
prior vinblastine/prednisone was monitored with a
wait and see approach after smoking cessation. Of 12
patients initially diagnosed with SS-m (n = 6) or MS-
LCH (n = 6), 11 were considered to be eligible for
MACOP-B. One elderly MS-LCH patient with severe
cardiologic comorbidities was deemed unfit for chemo-
therapy and treated with prednisone monotherapy.
Characteristics of patients included in the study are
shown in Table 1.
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All 11 patients treated with MACOP-B completed the
planned 12 cycles and were assessable for response after
6 and 12 weeks. After 6 weeks overall response rate
(ORR) was 100 % [6 CR (55 %) and 5 PR (45 %)]. After
12 weeks, at the final evaluation ORR was 100 % with 8
CR (73 %) and 3 PR (27 %). Four patients (36 %) (2 with
MS, 2 with SS-m disease) relapsed or progressed after
the achievement of initial response (1 after CR, 3 after
PR), and overall PFS was 64 % (Fig. 2a). Notably after a
median follow up of 6.7 years 7 of the 8 patients who
initially obtained a CR are still in first continuous CR,
with only 1 patient relapsed after 62 months, leading to
a DFS rate of 87.5 % (Fig. 2b). All three patients (2 MS,
1 SS-m) who obtained a partial response progressed
after 5, 6 and 8 months from the end of initial therapy.
One MS-LCH patient underwent autologous stem cell
transplantation (ASCT) after second line chemotherapy
and is still disease free after 6 years from ASCT. An-
other SS-m patient relapsed after 6 months and is cur-
rently undergoing second line chemotherapy and salvage
ASCT. The other 2 relapsed patients progressed and
died of disease related complications, as reported previ-
ously [9]. OS rate was 82 % after a median follow-up of
6.7 years (2 deaths), and 8 of the 9 alive patients are dis-
ease free at the last follow up (after 228, 216, 144, 96,
66, 47, 32, 24 months of follow-up) (Fig. 2c). Detailed
characteristics of single patients are described in Table 2.
There was no difference in outcome (in terms of OS
and PFS) between SS-m (n = 6) and MS-LCH patients
(n = 5), with 2 of 5 MS-LCH patients who did not obtain
a CR (3CR/2PR), compared to 1 of 6 SS-m patients
(1PR/5CR). One patient died and 2 patients progressed
or relapsed in both MS and SS-m groups (total 2 deaths,
3 progressions/1relapse) (Fig. 2d).
Overall, 8 patients were evaluated by PET scan. PET
scan performed at initial diagnosis was negative in 2 pa-
tients, so that 6 patients were evaluated at week 6 and
1 month after the completion of MACOP-B. Interim
PET performed at week 6 was negative in 4 of 6 patients,
predicting final CR in 3 of 4 cases. Two patients con-
verted from PR to CR from interim to final evaluation.
Of 5 patients with negative post-therapy PET, 4 are still
in first continuous CR.
Toxicities were mild and reversible, in line with previ-
ously published data on MACOP-B regimen in adult
Fig. 1 Treatment algorithm. Description of the treatment schedule and timing of staging procedures
Table 1 General patients characteristics
Factor N (%)
Number of patients 11
Age (median) 18–62 (40) years
Gender
F 6 (55 %)
M 5 (45 %)
SS-m 6 (55 %)
MS 5 (45 %)
Risk organ involvement 5 (45 %)
Lung 4 (36 %)
Spleen 1 (9 %)
Prior therapy 2 (18 %)
Radiotherapy 1 (9 %)
Topical steroids 1 (9 %)
N number, F female, M male, SS-m single system multifocal, MS multisystem
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patients [9, 11]. Briefly, 4 patients had treatment delay
due to grade 3 neutropenia, which was prevented by ad-
ministering prophylactic granulocyte-colony stimulating
factors (G-CSF) in subsequent cycles. Antibiotic prophy-
laxis with twice-weekly sulfamethoxazole-trimethoprim
was given to all patients. Overall, no episodes of febrile
neutropenia or serious infections were observed. Grade
3 self-limiting hypertransaminasemia was observed in
one patient after methotrexate administration, which re-
solved in 1 week and was prevented by a 30 % dose
reduction in the subsequent methotrexate cycles. No pa-
tient required treatment discontinuation.
Discussion
In this report we present the updated long term results
of our experience with the MACOP-B regimen in the
treatment of adult SS-m and MS-LCH. With a CR rate
of 73 %, an OS rate of 82 % and a PFS rate of 64 % these
data confirm that MACOP-B is very effective in adult
LCH, inducing long term complete responses in a
Fig. 2 OS, PFS, DFS curves. a Progression-free survival of 11 adult LCH patients treated with the MACOP-B regimen in a 20-year period.
b Disease-free survival of 8 adult LCH patients who obtained a CR after MACOP-B regimen. c Overall survival of 11 adult LCH patients
treated with the MACOP-B regimen in a 20-year period. d Progression-free survival of 6 SS-m LCH and 5 MS LCH patients treated with the
MACOP-B regimen in a 20-year period
Table 2 Detailed characteristics and outcome of the 11 LCH patients included in the study
Patient N° Disease type (SS-m vs MS) Response after MACOP-B Relapse/Progression DFS/PFS Status
1 SS-m CR No 144+ Alive (CR)
2 MS PR Yes 8 Dead (PD)
3 SS-m CR Yes 62 Dead (PD)
4 MS CR No 228+ Alive (CR)
5 SS-m CR No 216+ Alive (CR)
6 MS PR Yes 5 Alive (II CR, +66 m after ASCT)
7 SS-m CR No 96+ Alive (CR)
8 MS CR No 47+ Alive (CR)
9 MS CR No 32+ Alive (CR)
10 SS-m CR No 24+ Alive (CR)
11 SS-m PR Yes 6 Alive (PD, ASCT ongoing)
N number, SS-m single system multifocal, MS multisystem, CR complete response, PR partial response, PD progressive disease, DFS disease-free survival, PFS
progression-free survival, m months, ASCT autologous stem cell transplant
Derenzini et al. BMC Cancer  (2015) 15:879 Page 4 of 6
significant fraction of patients. Regarding overall efficacy,
these data are in line with the results of the LCH-III
pediatric trial [5], but it should be noted that the dur-
ation of therapy is about 4-fold longer in the LCH-III
pediatric protocol (12 months vs 3 months). As 87 % of
patients obtaining a CR after MACOP-B are still disease
free after a median follow-up of 6.7 years, these data in-
dicate that long term disease control is achievable in
adults without maintenance therapy, and highlight the
curative potential of this therapy. These data reinforce
the concept that the primary therapeutic aim in adult
LCH should be the quality of initial response rather than
long term maintenance to prevent recurrences. More-
over, the application of pediatric protocols in adults is
generally difficult due poor tolerance, and in fact the
LCHA1 trial was closed prematurely due to unaccept-
able toxicity [3]. Furthermore, multiple studies recently
reported suboptimal efficacy of pediatric approaches in
adults [3, 7]. The high efficacy of MACOP-B may also
suggest a role for antracyclines and cyclophosphamide in
adult LCH, in line with previous reports investigating
dose dense regimens [12, 13], and with anecdotal case
reports suggesting efficacy of antracycline based regi-
mens in case of lymphomas or leukemias coexisting with
LCH [14, 15]. Our data also compare favorably with re-
cently published data with front line 2-CdA [7], which is
widely used in adults. Regarding the role of PET scan,
these results suggest that this imaging modality should
be part of the diagnostic workflow of adult LCH pa-
tients, since the majority of our patients (6 of 8 patients)
were PET positive at the moment of initial diagnosis. Al-
though larger studies will be needed to assess the value
of PET in the setting of response evaluation, the fact that
4 of 5 patients with negative post-therapy PET are in
first continuous CR supports further evaluation of PET
scan also in this context.
Conclusions
In summary, in this report we confirmed high efficacy of
MACOP-B regimen in adult SS-m or MS-LCH. The
quality of initial response seems to be an important de-
terminant of the final outcome, as most patients obtain-
ing initial CR, achieve long-term remission and are
eventually cured with this approach. However due to the
retrospective nature of this study and to the small sam-
ple size we could not analyze the differential efficacy of
this regimen in SS-m vs MS-LCH and RO+ vs RO- pa-
tients, and future efforts should be aimed at building risk
adapted treatment algorithms, as a result of prospective
randomized trials. Our understanding of the biology of
LCH is rapidly improving and new druggable targets
such as BRAF mutations [16] were recently identified.
Vemurafenib showed preliminary evidence of efficacy
[17], but no data are available yet on the long term
efficacy of this therapy in adult LCH. In conclusion, we
believe that the findings of this study provide the proof
of principle for further testing of dose intense regimens
in adult LCH, as treatment intensity and quality of initial
response rather than treatment duration or maintenance
therapy emerged as important determinants of the final
outcome.
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